The role of neutrophils in myocardial ischemia-reperfusion injury

Cardiovascular Research

Volumn 43, Issue 4, 1999, Pages 860-878

  Jordan, James E ^a   Zhao, Zhi Qing ^a   Vinten Johansen, Jakob ^a  

^a Carlyle Fraser Heart Center   (United States)

Author keywords

Adenosine; Endothelium; Infarction; Inflammation; Monoclonal antibodies; Neutrophils; Nitric oxide; Reperfusion injury

Indexed keywords

ADENOSINE; CELL ADHESION MOLECULE; GLYCOPROTEIN; L SELECTIN; NITRIC OXIDE; PADGEM PROTEIN;

ENDOTHELIUM CELL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ADENOSINE; ANIMALS; ANTIBODIES, MONOCLONAL; CELL ADHESION; CELL ADHESION MOLECULES; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIUM, VASCULAR; MODELS, CARDIOVASCULAR; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEUTROPHILS; NITRIC OXIDE;

EID: 0032869566     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00187-X     Document Type: Review

References (190)

1. --forming NADPH oxidase of the phagocytes: nature, mechanisms of activation and function. [Review]. Biochim Biophys Acta. 853:1986;65-89.
2. Rotrosen D. The respiratory burst oxidase. In: Gallin JI et al., editors, Inflammation: basic principles clinical correlates, 2nd edition, New York: Raven Press, 1992, pp. 589-601, Ch. 29.
3. Deisher T.A., Garcia I., Harlan J.M. Cytokine-induced adhesion molecule expression on human umbilical vein endothelial cells is not regulated by cyclic adenosine monophosphate accumulation. Life Sci. 53:1993;365-370.
4. Svendsen J.H. The microcirculation of the heart with special reference to the role of reactive oxygen metabolites in the microvascular reperfusion injury [Review]. Dan Med Bull. 41:1994;526-540.
5. Svendsen J.H. Myocardial capillary permeability for small hydrophilic indicators during normal physiological conditions and after ischemia and reperfusion [Review]. Acta Physiol Scand. 603:1991;119-123.
6. Svendsen J.H., Bjerrum P.J. Effects of exogenous oxygen derived free radicals on myocardial capillary permeability, vascular tone, and incidence of ventricular arrhythmias in the canine heart. Cardiovasc Res. 26:1992;1181-1188.
7. McIntyre T.M., Patel K.D., Zimmerman G.A., Prescott S.M. Oxygen radical-mediated leukocyte adherence. Granger D.N., Schmid-Schönbein G.W. Physiology and pathophysiology of leukocyte adhesion. 1995;261-277 Oxford University Press, New York.
8. Gryglewski R.J., Palmer R.M.J., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature. 320:1986;454-460.
9. Rubanyi G.M., Vanhoutte P.M. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 250:1986;H822-H827.
10. Beckman J.S., Crow J.P. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans. 21:1993;330-334.
11. Beckman J.S., Wink D.A., Crow J.P. Nitric oxide and peroxynitrite. Feelisch M., Stamler J.S. Methods in nitric oxide research. 1996;61-70 Wiley, West Sussex.
12. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol. 271:1996;C1424-C1437.
13. Liu S., Beckman J.S., Ku D.D. Peroxynitrite, a product of superoxide and nitric oxide, produces coronary vasorelaxation in dogs. J Pharmacol Exp Ther. 268:1994;1114-1121.
14. Argenbright L.W. Inflammatory mediators, cytokines, and leukocyte adhesion in postcapillary venules. Granger D.N., Schmid-Schönbein G.W. Physiology and pathophysiology of leukocyte adhesion. 1995;171-184 Oxford University Press, New York.
15. Lefer A.M., Campbell B., Scalia R., Lefer D.J. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion. Roles of selectins. Circulation. 98:1998;1322-1328.
16. Siminiak T., Flores N.A., Sheridan D.J. Neutrophil interactions with endothelium and platelets: possible role in the development of cardiovascular injury [Review]. Eur Heart J. 16:1995;160-170.
17. Schmid-Schönbein G.W. Capillary plugging by granulocytes and the no-reflow phenomenon in the microcirculation. Fed Proc. 46:1987;2397-2401.
18. Lefer A.M., Tsao P.S., Lefer D.J., Ma X.-L. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J. 5:1991;2029-2034.
19. Lefer A.M., Ma X.-L., Weyrich A., Lefer D.J. Endothelial dysfunction and neutrophil adherence as critical events in the development of reperfusion injury. Agents Actions Suppl. 41:1993;127-135.
20. Lefer D.J., Nakanishi K., Vinten-Johansen J., Ma X.-L., Lefer A.M. Cardiac venous endothelial dysfunction after myocardial ischemia and reperfusion in dogs. Am J Physiol. 263:1992;H850-H856.
21. Boyle E.M., Pohlman T.H., Cornejo C.J., Verrier E.D. Endothelial cell injury in cardiovascular surgery: Ischemia-reperfusion. Ann Thorac Surg. 62:1996;1868-1875.
22. Gaboury J.P., Anderson D.C., Kubes P. Molecular mechanisms involved in superoxide-induced leukocyte-endothelial cell interactions in vivo. Am J Physiol. 266:1994;H637-H642.
23. Toothill V.J., Van Mourik J.A., Niewenhuis H.K., Metzelaar M.J., Pearson J.D. Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells. J Immunol. 145:1990;283-291.
24. Lorant D.E., Patel K.D., McIntyre T.M., et al. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. J Cell Biol. 115:1991;223-234.
25. Sluiter W., Pietersma A., Lamers J.M.J., Koster J.F. Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. J Cardiovasc Pharmacol. 22:(Suppl 4):1993;S37-S44.
26. Weyrich A.S., Buerke M., Albertine K.H., Lefer A.M. Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium. J Leukocyte Biol. 57:1995;45-55.
27. Kubes P., Jutila M., Payne D. Therapeutic potential of inhibiting leukocyte rolling in ischemia/reperfusion. J Clin Invest. 95:1995;2510-2519.
28. Moore K.L., Patel K.D., Bruehl R.E., et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol. 128:1995;661-671.
29. Kukielka G.L., Hawkins H.K., Michael L., et al. Regulation of intercellular adhesion molecule-1 (ICAM-1) in ischemic and reperfused canine myocardium. J Clin Invest. 92:1993;1504-1516.
30. Youker K.A., Hawkins H.K., Kukielka G.L., et al. Molecular evidence for induction of intracellular adhesion molecule-1 in the viable border zone associated with ischemia-reperfusion injury of the dog heart. Circulation. 89:1994;2736-2746.
31. Albelda S.M., Muller W.A., Buck C.A., Newman P.J. Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J Cell Biol. 114:1991;1059-1068. Abstract.
32. Newman P.J., Berndt M.C., Gorski J., et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science. 247:1990;1219-1222. Abstract.
33. Muller W.A., Weigl S.A., Deng X., Phillips D.M. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med. 178:1993;449-460. Abstract.
34. Vaporciyan A.A., DeLisser H.M., Yan H.C., Mendiguren Thom S.R. Jr., Jones M.L., Wand P.A., Albelda S.M. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science. 262:1993;1580-1582. Abstract.
35. Ohto H., Maeda H., Shibata Y., et al. A novel leukocyte differentiation antigen: two monoclonal antibodies TM2 and TM3 define a 120-kd molecule present on neutrophils, monocytes, platelets, and activated lymphoblasts. Blood. 66:1985;873-881. Abstract.
36. Gumina R.J., Schultz J., Yao Z., et al. Antibody to PECAM-1 reduces myocardial infarct size. J Invest Med. 43:1995;312A, Abstract.
37. Elgebaly S.A., Hashmi F.H., Houser S.L., Allam M.E., Doyle K. Cardiac-derived neutrophil chemotactic factors: detection in coronary sinus effluents of patients undergoing myocardial revascularization. J Thorac Cardiovasc Surg. 103:1992;952-959.
38. Dreyer W.J., Smith C.W., Michael L.H., et al. Canine neutrophil activation by cardiac lymph obtained during reperfusion of ischemic myocardium. Circ Res. 65:1989;1751-1762.
39. McEver R.P., Cummings R.D. Role of PSGL-1 binding to selectins in leukocyte Recruitment. J Clin Invest. 100:1997;485-492.
40. Davenpeck K.L., Gauthier T.W., Albertine K.H., Lefer A.M. Role of P-selectin in microvascular leukocyte-endothelial interaction in splanchnic ischemia-reperfusion. Am J Physiol. 267:1994;H622-H630.
41. Geng J.-G., Bevilacqua M.P., Moore K.L., et al. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature. 343:1990;757-760.
42. Jerome S.N., Dore M., Paulson J.C., Smith C.W., Korthuis R.J. P-selectin and ICAM-1-dependent adherence reactions: role in the genesis of postischemic no-reflow. Am J Physiol. 266:1994;H1316-H1321.
43. Ohashi Y., Kawashima S., Hirata K., Akita H., Yokoyama M. Nitric oxide inhibits neutrophil adhesion to cytokine-activated cardiac myocytes. Am J Physiol. 272:1997;H2807-H2814.
44. Tonnesen M.G. Neutrophil-endothelial cell interactions: mechanisms of neutrophil adherence to vascular endothelium. J Invest Dermatol. 93:1989;53S-58S.
45. Ikeda U., Ikeda M., Kano S., Shimada K. Neutrophil adherence to rat cardiac myocyte by proinflammatory cytokines. J Cardiovasc Pharmacol. 23:1994;647-652.
46. Ma X.-L., Tsao P.S., Viehman G.E., Lefer A.M. Neutrophil-mediated vasoconstriction and endothelial dysfunction in low-flow perfusion-reperfused cat coronary artery. Circ Res. 69:1991;95-106.
47. Ma X.-L., Weyrich A.S., Lefer D.J., Lefer A.M. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res. 72:1993;403-412.
48. Tsao P.S., Lefer A.M. Time course and mechanism of endothelial dysfunction in isolated ischemic- and hypoxic-perfused rat hearts. Am J Physiol. 259:1990;H1660-H1666.
49. Sato H., Zhao Z.-Q., Vinten-Johansen J. L-Arginine inhibits neutrophil adherence and coronary artery dysfunction. Cardiovasc Res. 31:1996;63-72.
50. Sato H., Zhao Z.-Q., Jordan J.E., et al. Basal nitric oxide expresses endogenous cardioprotection during reperfusion by inhibition of neutrophil-mediated damage after surgical revascularization. J Thorac Cardiovasc Surg. 113:1997;399-409.
51. Tsao P.S., Aoki N., Lefer D.J., Johnson G., Lefer A.M. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation. 82:1990;1402-1412.
52. Dignan R.J., Dyke C.M., Abd-Elfattah A.S., et al. Coronary artery endothelial cell and smooth muscle dysfunction after global myocardial ischemia. Ann Thorac Surg. 53:1992;311-317.
53. Nakanishi K., Zhao Z.-Q., Vinten-Johansen J., et al. Coronary artery endothelial dysfunction after ischemia, blood cardioplegia, and reperfusion. Ann Thorac Surg. 58:1994;191-199.
54. Van Benthuysen K.M., McMurtry I.F., Horwitz L.D. Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro. J Clin Invest. 79:1987;265-274.
55. Nakanishi K., Vinten-Johansen J., Lefer D.J., et al. Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol. 263:1992;H1650-H1658.
56. Kaeffer N., Richard V., Francois A., et al. Preconditioning prevents chronic reperfusion-induced coronary endothelial dysfunction in rats. Am J Physiol. 271:1996;H842-H849.
57. Zhao Z.-Q., Nakamura M., Wang N.-P., et al. Infarct extension and dynamic coronary endothelial dysfunction in the late reperfusion phase. Circulation. 98:1998;I-796. Abstract.
58. Kloner R.A., Ganote C.E., Jennings R.B. The 'no-reflow' phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 54:1974;1496-1508.
59. Engler R.L., Schmid-Schönbein G.W., Pavelec R.S. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol. 111:1983;98-111.
60. Engler R.L., Dahlgren M.D., Peterson M.A., Dobbs A., Schmid-Schonbein G.W. Accumulation of polymorphonuclear leukocytes during 3-h experimental myocardial ischemia. Am J Physiol. 251:1986;H93-H100.
61. Engler R.L., Dahlgren M.D., Morris D., Peterson M.A., Schmid-Schonbein G. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol. 251:1986;H314-H322.
62. Romson J.L., Hook B.G., Kunkel S.L., et al. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation. 67:1983;1016-1023.
63. Litt M.R., Jeremy R.W., Weisman H.F., Winkelstein J.A., Becker L.C. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia: Evidence for neutrophil-mediated reperfusion injury. Circulation. 80:1989;1816-1827.
64. 2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther. 280:1997;301-309.
65. Smith Egan J.W., Bugelski P.J., Hillegass L.M., Hill D.E., Griswold D.E. Temporal relation between neutrophil accumulation and myocardial reperfusion injury. Am J Physiol. 255:1988;H1060-H1068.
66. Dreyer W.J., Michael L.H., West M.W., et al. Neutrophil accumulation in ischemic canine myocardium: Insights into time course, distribution, and mechanism of localization during early reperfusion. Circulation. 84:1991;400-411.
67. Kubes P., Kurose I., Granger D.N. NO donors prevent integrin-induced leukocyte adhesion but not P-selectin-dependent rolling in postischemic venules. Am J Physiol. 267:1994;H931-H937.
68. Frame L.H., Lopez J.A., Khaw B.A., et al. Early membrane damage during coronary reperfusion in dogs: detection by radiolabelled anticardiac myosin (Fab′)2. J Clin Invest. 72:1983;535-544.
69. Farb A., Kolodgie F.D., Jenkins M., Virmani R. Myocardial infarct extension during reperfusion after coronary artery occlusion: Pathologic evidence. J Am Coll Cardiol. 21:1993;1245-1253.
70. Rochitte C.E., Lima J.A.C., Bluemke D.A., et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation. 98:1998;1006-1014. Abstract.
71. Albertine K.H., Weyrich A.S., Ma X.-L., et al. Quantification of neutrophil migration following myocardial ischemia and reperfusion in cats and dogs. J Leukocyte Biol. 55:1994;557-566.
72. Juneau C.F., Ito B.R., del Balzo U., Engler R.L. Severe neutrophil depletion by leucocyte filters or cytotoxic drug does not improve recovery of contractile function in stunned porcine myocardium. Cardiovasc Res. 27:1993;720-727.
73. Bolli R. Role of neutrophils in myocardial stunning after brief ischaemia: the end of a six year old controversy (1987-1993) [comment]. Cardiovasc Res. 27:1993;728-730.
74. Becker L.C. Do neutrophils contribute to myocardial stunning? [Review]. Cardiovasc Drugs Ther. 5:1991;909-913.
75. Entman M.L., Smith C.W. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. [Review]. Cardiovasc Res. 28:1994;1301-1311.
76. Thourani VH, Nakamura M, Duarte IG, et al. Ischemic preconditioning attenuates postischemic coronary artery endothelial dysfunction in a model of minimally invasive direct coronary artery bypass (MIDCAB). Circulation 1997; in press (Abstract).
77. Pabla R., Buda A.J., Flynn D.M., et al. Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res. 78:1996;65-72.
78. Campbell B, Shin YK, Lefer AM. Beneficial effects of N,N,N-trimethylsphingosine following ischemia and reperfusion in the isolated perfused rat heart. Cardiovasc Res 1998; in press.
79. Galiñanes M., Lawson C.S., Ferrari R., et al. Early and late effects of leukopenic reperfusion on the recovery of cardiac contractile function: Studies in the transplanted and isolated blood-perfused rat heart. Circulation. 88:1993;673-683.
80. Carlson R.E., Schott R.J., Buda A.J. Neutrophil depletion fails to modify myocardial no reflow and functional recovery after coronary reperfusion. J Am Coll Cardiol. 14:1989;1803-1813.
81. Kofsky E.R., Julia P.L., Buckberg G.D., Quillen J.E., Acar C. Studies of controlled reperfusion after ischemia. XXII. Reperfusate composition: Effects of leukocyte depletion of blood and blood cardioplegic reperfusates after acute coronary occlusion. J Thorac Cardiovasc Surg. 101:1991;350-359.
82. Schmidt F.E.J., MacDonald M.J., Murphy C.O., et al. Leukocyte depletion of blood cardioplegia attenuates reperfusion injury. Ann Thorac Surg. 62:1996;1691-1696.
83. Gott J.P., Cooper W.A., Schmidt F.E.J., et al. Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg. 66:1998;747-753.
84. Sheridan F.M., Dauber I.M., McMurtry I.F., Lesnefsky E.J., Horwitz L.D. Role of leukocytes in coronary vascular endothelial injury due to ischemia and reperfusion. Circ Res. 69:1991;1566-1574.
85. Weyrich A.S., Ma X.-L., Lefer D.J., Albertine K.H., Lefer A.M. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest. 91:1993;2620-2629.
86. Lefer D.J., Flynn D.M. Effects of a monoclonal antibody directed against P-selectin after myocardial ischemia and reperfusion. Am J Physiol. 39:1996;H88-H98.
87. Buerke M., Weyrich A.S., Murohara T., et al. Humanized monoclonal antibody DREG-200 directed against L-selectin protects in feline myocardial reperfusion injury. J Pharmacol Exp Ther. 271:1994;134-142.
88. Ma X.-L., Weyrich A.S., Lefer D.J., et al. Monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium. Circulation. 88:1993;649-658.
89. Ma X.-L., Tsao P.S., Lefer A.M. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest. 88:1991;1237-1243.
90. Lefer D.J., Shandelya S.M., Serrano C.V. Jr., et al. Cardioprotective actions of a monoclonal antibody against CD-18 in myocardial ischemia-reperfusion injury. Circulation. 88:1993;1779-1787.
91. Ma X.-L., Lefer D.J., Lefer A.M., Rothlein R. Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation. 86:1992;937-946.
92. Zhao Z.-Q., Lefer D.J., Sato H., Buda A.J., Vinten-Johansen J. Monocolonal antibody to ICAM-1 reduces infarct size following coronary occlusion-reperfusion in the anesthetized rabbit. J Leukocyte Biol. 62:1997;292-300.
93. Murohara T., Buerke M., Lefer A.M. Polymorphonuclear leukocyte-induced vasocontraction and endothelial dysfunction. Role of selectins. Arterioscler Thromb. 14:1994;1509-1519.
94. Entman M.L., Youker K., Shoji T., et al. Neutrophil induced oxidative injury of cardiac myocytes. J Clin Invest. 90:1992;1335-1345.
95. Arai M., Lefer D.J., So T., et al. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol. 27:1996;1278-1285.
96. x analogue does not reduce myocardial infarct size after ischemia and reperfusion in dogs. Circulation. 94:1996;542-546.
97. x-containing oligosaccharide attenuates myocardial reperfusion injury in cats. J Clin Invest. 93:1994;1140-1148.
98. x analog attenuates neutrophil accumulation and myocardial necrosis after ischemia and reperfusion. Circulation. 90:1994;2390-2401.
99. Johnson G., Tsao P.S., Mulloy D., Lefer A.M. Cardioprotective effects of acidified sodium nitrite in myocardial ischemia with reperfusion. J Pharmacol Exp Ther. 252:1990;35-41.
100. Toyoaki M., Parkinson S.J., Waldman S.A., Lefer A.M. Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets: Role of protein kinase C. Arterioscler Thromb Vasc Biol. 15:1995;2068-2207.
101. 2 generation, respectively. J Clin Invest. 85:1990;1150-1157.
102. Kubes P., Suzuki M., Granger N. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 88:1991;4651-4655.
103. Clancy R.M., Leszczynska-Piziak J., Abramson S.B. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest. 90:1992;1116-1121.
104. DeCaterina R., Libby O., Peng H., et al. Nitric oxide decreases cytokine-induced endothelial activation. J Clin Invest. 96:1995;60-68.
105. Armstead V.E., Minchenko A.G., Schuhl R.A., et al. Regulation of P-selectin expression in human endothelial cells by nitric oxide. Am J Physiol. 42:1997;H740-H746.
106. Lefer D.J., Nakanishi K., Vinten-Johansen J. Endothelial and myocardial cell protection by a cysteine-containing nitric oxide donor after myocardial ischemia and reperfusion. J Cardiovasc Pharmacol. 22:(Suppl 7):1993;S34-S43.
107. Lefer D.J., Nakanishi K., Johnston W.E., Vinten-Johansen J. Antineutrophil and myocardial protection actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion in dogs. Circulation. 88:1993;2337-2350.
108. Siegfried M.R., Carey C., Ma X.-L., Lefer A.M. Beneficial effects of SPM-5185, a cysteine-containing NO donor in myocardial ischemia-reperfusion. Am J Physiol. 263:1992;H771-H777.
109. Siegfried M.R., Erhardt J., Rider T., Ma X.-L., Lefer A.M. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J Pharmacol Exp Ther. 260:1992;668-675.
110. Ma X.-L., Lefer A.M., Zipkin R.E. S-Nitroso-N-acetylpenicillamine is a potent inhibitor of neutrophil-endothelial interaction. Endothel. 1:1993;31-39.
111. Guo J.-P., Murohara T., Buerke M., Scalial R., Lefer A.M. Direct measurement of nitric oxide release from vascular endothelial cells. J Appl Physiol. 81:1996;774-779.
112. Delyani J.A., Nossuli T.O., Scalia R., et al. S-nitrosylated tissue-type plasminogen activator protects against myocardial ischemia/reperfusion injury in cats: role of the endothelium. J Pharmacol Exp Ther. 279:1996;1174-1180.
113. Lefer A.M., Lefer D.J. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc Res. 32:1996;743-751.
114. Johnson G., Tsao P.S., Lefer A.M. Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit Care Med. 19:1991;244-252.
115. Siegfried M.R., Erhardt J., Rider T., Ma X.-L., Lefer A.M. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J Pharmacol Exp Ther. 260:1992;668-675.
116. Lefer A.M., Lefer D.J. Therapeutic role of nitric oxide donors in the treatment of cardiovascular disease. Drugs Future. 19:1994;665-672.
117. Egdell R.M., Siminiak T., Sheridan D.J. Modulation of neutrophil activity by nitric oxide during acute myocardial ischaemia and reperfusion [Review]. Basic Res Cardiol. 89:1994;499-509.
118. Lefer A.M. Attenuation of myocardial ischemia-reperfusion injury with nitric oxide replacement therapy [Review]. Ann Thorac Surg. 60:1995;847-851.
119. Pabla R., Buda A.J., Flynn D.M., Salzberg D.B., Lefer D.J. Intracoronary nitric oxide improves postischemic coronary blood flow and myocardial contractile function. Am J Physiol. 269:1995;H1113-H1121.
120. Sato H., Zhao Z.-Q., McGee D.S., et al. Supplemental L-arginine during cardioplegic arrest and reperfusion avoids regional postischemic injury. J Thorac Cardiovasc Surg. 110:1995;302-314.
121. Pernow J., Uriuda Y., Wang Q.D., et al. The protective effect of L-arginine on myocardial injury and endothelial function following ischaemia and reperfusion in the pig. Eur Heart J. 15:1994;1712-1719.
122. Weyrich A.S., Ma X.-L., Lefer A.M. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation. 86:1992;279-288.
123. Davenpeck K.L., Gauthier T.W., Lefer A.M. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology. 107:1994;1050-1058. see comments.
124. Williams M.W., Taft C.S., Ramnauth S., Zhao Z.-Q., Vinten-Johansen J. Endogenous nitric oxide protects against myocardial reperfusion injury in the rabbit. FASEB J. 8:1995;A559. Abstract.
125. Schulz R., Wambolt R. Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischaemia-reperfusion injury. Cardiovasc Res. 30:1995;432-439.
126. Cope J.T., Banks D., Laubach V.E., et al. Sodium nitroprusside exacerbates myocardial ischemia-reperfusion injury. Ann Thorac Surg. 64:1997;1656-1660.
127. Cohen M.V., Liu G.S., Downey J.M. Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits. Circulation. 84:1991;341-349.
128. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;287-289.
129. Hattler B.G., Gorcsan I.J., Shah N., et al. A potential role for nitric oxide in myocardial stunning. J Card Surg. 9:1994;425-429.
130. Patel V.C., Yellon D.M., Singh K.J., Neild G.H., Woolfson R.G. Inhibition of nitric oxide limits infarct size in the in situ rabbit heart. Biochem Biophys Res Commun. 194:1993;234-238.
131. Woolfson R.G., Patel V.C., Neild G.H., Yellon D.M. Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation. 91:1995;1545-1551.
132. Zweier J.L., Wang P., Kuppusamy P. Direct measurement of nitric oxide generation in the ischemic heart using electron paramagnetic resonance spectroscopy. J Biol Chem. 270:1995;304-307.
133. Muijsers R.B.R., Folkerts G., Henricks P.A.J., Sadeghi-Hashjin G., Nijkamp F.P. Peroxynitrite: A two-faced metabolite of nitric oxide. Life Sci. 60:1997;1833-1845.
134. Silva P.H., Dillon D., Van Wylen D.G. Adenosine deaminase inhibition augments interstitial adenosine but does not attenuate myocardial infarction. Cardiovasc Res. 29:1995;616-623.
135. Van Wylen D.G., Schmit T.J., Lasley R.D., Gingell R.L., Mentzer R.M. Jr. Cardiac microdialysis in isolated rat hearts: interstitial purine metabolites during ischemia. Am J Physiol. 262:1992;H1934-H1938.
136. Van Wylen D.G.L. Effect of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia. Circulation. 89:1994;2283-2289.
137. 2 receptor on human neutrophils. J Immunol. 135:1985;1366-1371.
138. Schrier D.J., Imre K.M. The effects of adenosine agonists on human neutrophil function. J Immunol. 137:1986;3284-3289.
139. 2 receptors. J Immunol. 148:1992;2201-2206.
140. 2 receptor agonists. J Immunol. 155:1995;333-338.
141. 2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium. Am J Physiol. 271:1996;H1456-H1464.
142. 3 adenosine receptor activation reduces PMN-endothelial cell interaction without effect on free radicals and degranulation. Circulation. 98:1998;I-666. Abstract.
143. McGarrity S.T., Stephenson A.H., Webster R.O. Regulation of human neutrophil functions by adenine nucleotides. J Immunol. 142:1989;1986-1994.
144. Firestein G.S., Bullough D.A., Erion M.D., et al. Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins. J Immunol. 154:1995;326-334.
145. 2 receptors, adenosine inhibits the upregulation of Mac-1 (CD11b/CD18) expression on FMLP-stimulated neutrophils. Am J Resp Cell Mol Biol. 9:1993;179-185.
146. 2 integrins and L-selectin of human polymorphonuclear leukocytes in vitro. J Leukocyte Biol. 59:1996;671-682.
147. Bouma M.G., van dan Wildenberg F.A., Buurman W.A. Adenosine inhibits cytokine release and expression of adhesion-molecules by activated human endothelial cells. Am J Physiol. 270:1996;C522-C529.
148. Bullough D.A., Magill M.J., Mullane K.M., Firestein G.S. Carbohydrate- and CD18-dependent neutrophil adhesion to cardiac myocytes: effects of adenosine. Cardiovasc Res. 32:1996;328-334.
149. Cronstein B.N., Levin R.I., Belanoff J., Weissmann G., Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 78:1986;760-770.
150. Olafsson B., Forman M.B., Puett D.W., et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation. 76:1987;1135-1145.
151. Pitarys C.J., Virmani R., Vildibill H.D. Jr., Jackson E.K., Forman M.B. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation. 83:1991;237-247.
152. Zhao Z.-Q., McGee D.S., Nakanishi K., et al. Receptor-mediated cardioprotective effects of endogenous adenosine are exerted primarily during reperfusion after coronary occlusion in the rabbit. Circulation. 88:1993;709-719.
153. Nichols W.W., Nicolini F.A., Yang B.C., et al. Adenosine protects against attenuation of flow reserve and myocardial function after coronary occlusion and reperfusion. Am Heart J. 127:1994;1201-1211.
154. 2-receptor agonists on myocardial reperfusion injury. Am Heart J. 123:1992;332-338.
155. 2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J Cardiovasc Pharmacol. 22:1993;89-96.
156. Kirklin J.K., Westaby S., Blackstone E.H., et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 86:1983;845-857.
157. Cavarocchi N.C., England M.D., Schaff H.V., et al. Oxygen free radical generation during cardiopulmonary bypass: correlation with complement activation. Circulation. 74:1986;III130-III133.
158. Chenoweth D.E. Complement activation during cardiopulmonary bypass. Utley J.R., Betleski R. Pathophysiology and techniques of cardiopulmonary bypass. second ed :1983;49-60 Williams and Wilkins, Baltimore.
159. Davies S.W., Bailey J., Wedzicha J.A., Rudd R.M. Complement activation and lung permeability during cardiopulmonary bypass. Ann Thorac Surg. 51:1991;693-697.
160. Gillinov A.M., DeValeria P.A., Winkelstein J.A. Complement inhibition with soluble complement receptor Type 1 in cardiopulmonary bypass. Ann Thorac Surg. 55:1993;619-624.
161. Gillinov A.M., Redmond J.M., Winkelstein J.A., et al. Complement and neutrophil activation during cardiopulmonary bypass: a study in the complement-deficient dog. Ann Thorac Surg. 57:1994;345-352.
162. Dreyer W.J., Michael L.H., Nguyen T., et al. Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. Circ Res. 71:1992;1518-1524.
163. McManus L.M., Kolb W.P., Crawford M.H., et al. Complement localization in ischemic baboon myocardium. Lab Invest. 48:1983;436-447.
164. Rossen R.D., Swain J.L., Michael L.H., et al. Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle. Circ Res. 57:1985;119-130.
165. Mathey D., Schofer J., Schafer H.J., et al. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J. 15:1994;418-423.
166. Ivey C.L., Williams F.M., Collins P.D., Jose P.J., Williams T.J. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8. J Clin Invest. 95:1995;2720-2728.
167. Riley RD, Sato H, Zhao Z-Q, et al. Recombinant human complement C5a receptor antagonist reduces infarct size following surgical revascularization. Circulation 1997;in press (Abstract).
168. Jagels M.A., Chambers J.D., Arfors K.E., Hugli T.E. C5a- and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. Blood. 85:1995;2900-2909.
169. Foreman K.E., Glovsky M.M., Warner R.L., Horvath S.J., Ward P.A. Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation. 20:1996;1-9.
170. Foreman K.E., Vaporciyan A.A., Bonish B.K., et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 94:1994;1147-1155.
171. Engler R.L., Roth D.M., del Balzo U., Ito B.R. Intracoronary C5a induces myocardial ischemia by mechanisms independent of the neutrophil: leukocyte filters desensitize the myocardium to C5a. FASEB J. 5:1991;2983-2991.
172. Shandelya S.M., Kuppusamy P., Herskowitz A., Weisfeldt M.L., Zweier J.L. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation. 88:1993;2812-2826.
173. Buerke M., Murohara T., Lefer A.M. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 91:1995;393-402.
174. Amsterdam E.A., Stahl G.L., Pan H.L., et al. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 268:1995;H448-H457.
175. Tofukuji M., Stahl G.L., Agah A., et al. Anti-C5A monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. J Thorac Cardiovasc Surg. 116:1998;1060-1068.
176. Weisman H.F., Bartow T., Leppo M.K., et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 249:1990;146-151.
177. Gralinski M.R., Wiater B.C., Assenmacher A.N., Lucchesi B.R. Selective inhibition of the alternative complement pathway by sCR1 [desLHR-A] protects the rabbit isolated heart from human complement-mediated damage. Immunopharmacology. 34:1996;79-88.
178. Homeister J.W., Lucchesi B.R. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol. 34:1994;17-40.
179. Black S.C., Gralinski M.R., Friedrichs G.S., et al. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res. 29:1995;629-636.
180. Gralinski M.R., Park J.L., Ozeck M.A., Wiater B.C., Lucchesi B.R. LU 51198, a highly sulphated, low-molecular-weight heparin derivative, prevents complement-mediated myocardial injury in the perfused isolated rabbit heart. J Cardiovasc Pharmacol Therapeut. 282:1997;554-560.
181. Friedrichs G.S., Kilgore K.S., Manley P.J., Gralinski M.R., Lucchesi B.R. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res. 75:1994;701-710.
182. Kouretas P.C., Myers A.K., Kim Y.D., et al. Heparin and nonanticoagulant heparin preserve regional myocardial contractility after ischemia-reperfusion injury: Role of nitric oxide. J Thorac Cardiovasc Surg. 115:1998;440-449.
183. Suzuki H., Zweifach B.W., Forrest M.J., Schmid-Schönbein G.W. Modification of leukocyte adhesion in spontaneously hypertensive rats by adrenal corticosteroids. J Leukocyte Biol. 57:1995;20-26.
184. Node K., Kitakaze M., Kosaka H., et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: Role of nitric oxide and calcium-activated potassium channels. Circulation. 96:1997;1953-1963.
185. Wanna F.S., Obayashi D.Y., Young J.N., DeCampli W.M. Simultaneous manipulation of the nitric oxide and prostanoid pathways reduces myocardial reperfusion injury. J Thorac Cardiovasc Surg. 110:1995;1054-1062.
186. Seth S.D., Maulik M., Manchanda S.C., Maulik S.K. Role of aspirin in modulating myocardial ischemic reperfusion injury. Agents Actions. 41:1994;151-155.
187. Curtis W.E., Gillinov A.M., Wilson I.C., et al. Inhibition of neutrophil adhesion reduces myocardial infarct size. Ann Thorac Surg. 56:1993;1069-1072. discussion, p. 1072.
188. Kimura Y., Iyengar J., Engelman R.M., Das D.K. Prevention of myocardial reperfusion injury in experimental coronary revascularization following ischemic arrest by a novel antiinflammatory drug, ONO-3144. J Cardiovasc Pharmacol. 16:1990;992-999.
189. Wainwright C.L., Parratt J.R. Failure of cyclo-oxygenase inhibition to protect against arrhythmias induced by ischaemia and reperfusion: implications for the role of prostaglandins as endogenous myocardial protective substances. Cardiovasc Res. 25:1991;93-100.
190. Janero D.R., Burghardt B., Lopez R., Cardell M. Influence of cardioprotective cyclooxygenase and lipoxygenase inhibitors on peroxidative injury to myocardial-membrane phospholipid. Biochem Pharmacol. 38:1989;4381-4387.